Robotic removal of stomach GISTs in difficult anatomic locations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm, phase II study planning to enroll 182 adults with localized gastric GISTs at special anatomic sites for robotic radical surgery. Eligible patients (age 18–75, tumor 2–5 cm, ECOG 0–1, no distant metastasis or prior neoadjuvant therapy) will undergo robotic resection and be followed for perioperative and postoperative outcomes. Postoperative treatment decisions will be made jointly by clinicians and patients according to usual clinical practice. The primary emphasis is on surgical safety, feasibility, and oncologic outcomes such as R0 resection rate, intraoperative complications, and functional preservation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 75 years, regardless of sex.
* Diagnosis of GIST located at a special anatomic site confirmed preoperatively by endoscopy/endoscopic ultrasound, CT, or MRI.
* Preoperative imaging suggests a tumor diameter between 2 cm and 5 cm.
* No prior neoadjuvant therapy (e.g., imatinib) administered.
* Expected survival period ≥ 6 months.
* Preoperative assessment indicates feasibility for robotic surgery.
* Preoperative examinations show no evidence of distant metastasis or direct invasion into adjacent organs.
* Preoperative ECOG Performance Status score of 0 or 1.
* Preoperative ASA Physical Status classification of I to III.
* The subject has read and fully understood the patient information sheet and provided written informed consent.

Exclusion Criteria:

* History of previous upper abdominal surgery (except laparoscopic cholecystectomy).
* History of previous gastrectomy, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD).
* Previous administration of neoadjuvant therapy (e.g., imatinib).
* Presence of other active malignancies within the past 5 years or concurrently. (Note: Patients with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervical carcinoma in situ, breast carcinoma in situ, Stage I lung cancer, or Stage I colorectal cancer, may be enrolled.)
* Requirement for concurrent surgery for other diseases.
* Emergency surgery performed due to tumor-related complications (bleeding, obstruction, or perforation).
* Arterial/venous thrombotic events within 6 months prior to screening, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (excluding thrombosis related to prior chemotherapy venous catheters deemed resolved by the investigator), and pulmonary embolism.
* Myocardial infarction within 6 months prior to surgery, or poorly controlled arrhythmia (including QTc interval ≥450 ms for males or ≥470 ms for females, calculated using Fridericia's formula).
* Cardiac insufficiency classified as NYHA Class III-IV, or left ventricular ejection fraction (LVEF) \<50% on cardiac ultrasound.
* Ventilatory dysfunction: FEV1 \<50% of predicted value.
* Clinically symptomatic pleural or abdominal effusion requiring clinical intervention.
* Human Immunodeficiency Virus (HIV) infection.
* Active pulmonary tuberculosis.
* History or presence of interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired pulmonary function that may interfere with the detection or management of suspected drug-related pulmonary toxicity.
* Any active infection requiring systemic anti-infective therapy within 14 days prior to surgery; except for prophylactic antibiotic therapy (e.g., for urinary tract infection or chronic obstructive pulmonary disease).
* Concurrent participation in another clinical trial involving surgical treatment.
* History of alcohol abuse, drug abuse, or substance abuse. (Note: Patients who have ceased alcohol consumption may be enrolled.)
* Patients deemed likely to be non-compliant with medical advice or medication regimens, or with incomplete data that may affect efficacy or safety assessment.
* Pregnant or lactating female patients.
* Any condition that may increase the risk associated with study participation, or other severe, acute, or chronic diseases, or any other situation that, in the investigator's judgment, makes the patient unsuitable for clinical study participation.

Where it's running

• The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Qiang Zhang, Ph.D
• Email: zhqsq@qq.com
• Phone: +86 18851727696

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Living long-term with advanced GIST on tyrosine kinase inhibitors

  This observational project will collect medical records and patient questionnaires to see how long-term tyrosine kinase inhibitor treatment affects quality of life and survivorship for adults with advanced or metastatic GIST who have taken TKIs for at least two years.

  Recruiting The Netherlands Cancer Institute · Amsterdam, North Holland · NCT07522762

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Off-clamp, sutureless robot-assisted partial nephrectomy vs conventional robot-assisted partial nephrectomy

  This trial tests whether removing a small kidney tumor without clamping the blood supply and without stitching the kidney bed preserves kidney function better than the standard robot-assisted surgery.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07888608

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

• Real-world use of BCL-2 inhibitor regimens in CLL/SLL

  This real-world study looks at how BCL-2 inhibitors are used and how patients with CLL or SLL fare in routine clinical practice.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07874451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.